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Use of PCR in routine diagnosis of treated and
untreated pulmonary tuberculosis
K Y Yuen, K S Chan, C M Chan, B S W Ho, L K Dai, P Y Chau, M H Ng
Abstract
Aims-To assess the routine use of a
polymerase chain reaction (PCR) assay
for the direct detection of Myco-
bacterium tuberculosis in expectorated
sputum specimens.
Methods-A pair of primers (20-mer)
were designed to amplify the 38 kilodal-
ton protein ofM tuberculosis. The speci-
ficity of the assay was evaluated in 31 M
tuberculosis strains, 15 atypical myco-
bacterium species, and several commen-
sal bacteria of the upper respiratory
tract. The assay was subsequently
applied to 519 sputum specimens from 85
inpatients of a chest hospital in Hong
Kong.
Results-An amplified product of 239
base pairs was found in allM tuberculosis
strains, standard strains ofM bovis, and
M africanum but not in the other bacter-
ial strains tested. For the 51 patients with
pulmonary radiographic lesions, the
diagnosis of pulmonary tuberculosis was
subsequently confirmed by both culture
and PCR in 41 of them. Five patients
who were treated before admission were
positive by PCR alone. All but one
patient in the control group (patients
with acute exacerbation of chronic
obstructive airway diseases) or those
with atypical mycobacterial diseases
were PCR negative. The PCR remained
positive after four weeks of anti-tubercu-
losis treatment in 29 patients, 16 of
whom had become culture negative.
Conclusion-This PCR assay is a useful
technique for the diagnosis of untreated
and recently treated cases of pulmonary
tuberculosis.
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Pulmonary tuberculosis remains an important
cause of morbidity and mortality (annual
notification of 6283 cases and 410 deaths in
1991) in our locality despite a high standard
of living.' For a specific diagnosis of this dis-
ease, the confirmed technique is the standard
culture which takes weeks before a positive
isolate can be identified and reported. Thus
even in the absence of a positive Ziehl-
Neelsen smear, the initiation of anti-tubercu-
losis treatment is often based on the presence
of suggestive radiological lesions. Because
early treatment can be effective in rendering
the patients non-infectious, a rapid, specific,
and sensitive diagnostic method would be
useful by avoiding the use of more invasive
diagnostic technique such as biopsy and the
side effects of unnecessary empirical antimi-
crobial treatment.
The polymerase chain reaction (PCR) has
been used to amplify Mycobacteria specific
target DNA sequences.23 Previous reports
have emphasised the general applicability of
PCR as a diagnostic tool by comparing the
results of culture and PCR assay on individ-
ual specimens.45 Though a prospective corre-
lation of clinical diagnosis, conventional
mycobacterial culture, and PCR assay was
conducted by Brisson-Noel,6 there was little
information regarding the use of this tech-
nique in the follow up study of specific
groups of patients. In this study PCR was
incorporated with the conventional microbio-
logical procedure in the initial diagnosis and
systematic follow up of a group of patients
with pulmonary diseases admitted to a chest
hospital in Hong Kong.
Methods
Four hundred and twenty five serial expecto-
rated sputum samples from 51 patients with
the following clinical features were included
in this study: (1) a history of productive
cough for more than 4 weeks; (2) chest radio-
graphic lesions suspicious of pulmonary
tuberculosis (patchy or nodular infiltrate in
upper lobes or superior segment of lower
lobes, bilateral upper lobe infiltrates with
patchy soft shadows with or without cavita-
tion, pneumonic change with a hilar adeno-
pathic shadow); and (3) absence of
malignancy by negative sputum cytology in
indicated cases. Two or more expectorated
sputum samples were collected in y-irradiated
disposable plastic containers before and 4
weeks after anti-tuberculosis treatment with
isoniazid, pyrazinamide, rifampicin and/or
ethambutol, streptomycin. Six patients were
already receiving treatment with anti-tubercu-
losis agents for less than 3 weeks when they
were admitted. As controls, 94 specimens
from 34 patients with acute exacerbation of
chronic obstructive airway diseases were test-
ed. These patients only received standard
antibacterial drugs for their chest infection
with Streptococcus pneumoniae, Haemophilus
influenzae, Branhamella catarrhalis and
unknown pathogens in some cases.
All samples were stored at - 20°C if not
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immediately processed. They were processed
and assayed under code by investigators
unaware of the clinical information. The sam-
ples were initially processed as routine spu-
tum specimens as described.7 Briefly, a direct
smear was prepared for auramine fluorescent
stain and if positive, Ziehl-Neelsen stain con-
firmation was performed. The specimens
were then decontaminated and digested with
an equal volume of Sputolysin (Oxoid) and
3% sodium hydroxide for 30 minutes at room
temperature.
The mixture was neutralised with 0-048M
NaH,PO4 (pH6-8) buffer and then cen-
trifuged at 5000 rpm for 30 minutes. The
sediment was resuspended in 400 ul of TE
(50 mM TRIS-5 mM EDTA, pH 8&0) buffer.
Each of two Lowenstein-Jensen agar slants
was inoculated with 100 ,ul of suspensions
and incubated at 37°C. The other half was
transferred to an Eppendorf tube for DNA
extraction.
DNA was extracted from the frozen
aliquots of concentrated clinical samples, as
described, with some modifications.8 After
digestion with lysozyme (1 mg/ml), the speci-
mens was lysed by heating at 95°C with an
alkaline sodium dodecyl sulphate solution,
followed by neutralisation with TRIS-HCI
buffer. DNA was extracted once with phenol-
chloroform, precipitated with ethanol and
resuspended in 100,ul sterile distilled water
for PCR,amplification.
Primer and probe sequences were selected
from the region of M tuberculosis genome
encoding the 38 kilodalton protein.58 No clin-
ically important homology was found
between the primer sequences with the other
known genomic sequences by computer
search of the information in GenBank. The
sequences of the primers were 5'-
TGACGTTGGC GGAGACCGGT-3' and
5'-GCTGAGCGGA GATGGCTAGC-3'.
The probe was located between the two
primers and its sequence was 5'-GCT-
GTTCAAC CTGTGGGGTC CGGC-
CTTTC-3'.5
The primers and probes were synthesised
on an Applied Biosystem 380B DNA synthe-
siser. They were successfully tested by PCR
with 30 different clinical isolates ofM tubercu-
losis and three standard strains ofM tuberculo-
sis complex. No false positive result occurred
with 35 different standard strains of bacteria
outside the M tuberculosis complex. These
PCR negative strains included M xenopi, M
malmoense, M szulgi, M chelonae, M gordonae,
M flavescens, M nonchromogenicum, M
kansasii, M simiae, M scrofulaceum, M avium,
M fortuitum, Corynebacterium and Nocardia
species. The primers were shown to be speci-
fic for M tuberculosis, M bovis, and M
africanum. No target band or hybridisation
with probe was found on PCR when other
bacterial strains and human leucocytes were
tested.
Each amplification reaction mixture (in a
final volume of 100 ,l) contained 10 mM
TRIS-HCI (pH 8 3), 50 mM KC1, 1-8mM
MgCl,, 0-15 mM each deoxynucleotide
triphosphate (Pharmacia), 75 pmol each of
the two primers and 2 units of thermostable
Taq DNA polymerase (Cetus). Each reaction
was overlaid with mineral oil (75 pl) to pre-
vent evaporation. The DNA in each reaction
was initially denatured by incubating at 95°C
for 5 minutes before 35 cycles of amplifica-
tion were performed with a programmable
thermal cycler (Coy, USA). Each amplifica-
tion cycle consisted of denaturation at 95'C
for 1-5 minutes, annealing at 59°C for 1-5
minutes and extension at 72°C for 1 minute.
At the end of the 35 cycles, the reactions
were maintained at 72°C for another 5 min-
utes for full extension of the desired PCR
products. Negative controls and several con-
trol reactions with serial dilutions of purified
M tuberculosis DNA down to 0-25 pg as posi-
tive controls were also carried out in each
run. Precautions to avoid false positive results
were taken in every assay, as described.10
Amplified DNA products including the
desired target of 239 base pairs were separat-
ed by electrophoresis on agarose gels and
transferred to Hybond-N nylon membrane
(Amersham) by Southern blotting.1I1
Hybridisation was done at 60°C overnight in
a solution containing 106cpm/ml Gamma 32P_
5' end labelled oligonucleotide probe.
Membranes were exposed to x-ray film
(Cronex; Dupont) in cassettes containing
intensifying screen overnight at -70°C.
Typical PCR findings were shown in the
figure. The results on the ethidium bromide
stained agrose gel were recorded and subse-
quently confirmed by probing.
Results
A total of 519 specimens were processed from
51 patients with chest radiographic lesions
suggestive of tuberculosis and 34 patients
with acute exacerbation of chronic obstruc-
tive airways disease. All 53 smear positive
specimens with subsequent positive culture
forM tuberculosis were positive on PCR (table
1). However, five out of the 63 smear nega-
tive culture positive specimens were missed
by the PCR assay (sensitivity 92%). Twenty
specimens from four patients with radio-
graphically suggestive lesions and one control
yielded atypical mycobacteria on culture (4M
avium intracellulare, 1 M chelonae). None of
their specimens was positive on PCR. With
respect to the 383 culture negative speci-
mens, PCR was positive in 57 specimens
which were collected from both groups of
patients (those initially culture positive for M
tuberculosis and those receiving empirical
treatment before admission) already receiving
treatment with anti-tuberculosis agents.
When the status of individual patients was
evaluated by the findings on multiple speci-
mens, all 41 patients with positive cultures for
M tuberculosis on admission were PCR posi-
tive (table 2). Though no documentation by
culture was possible for the six patients who
were already receiving treatment on admis-
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Typicalfindings of the 13CR assay on clinical specimens.
Lane 1-4: positive control reactions with serial dilutions ofpurifiedM tuberculosis DNA
down to 0-25 pg.
Lane 5: negative control reaction.
Lane M: molecular size marker, RF-DNA ofphage X-174, digested with Hae III.
Lanes 6, 7: persistent smear positive culture-positive specimens forM tuberculosis from a
patient 4 weeks after and before treatment.
Lane 8: smear negative, culture positive specimen.
Lanes 9, 10: persistent smear positive specimens turningfrom culture positive to culture
negative from a patient 4 weeks after and before treatment.
sion, five were PCR positive (of which two
were smear positive). The PCR negative
patient was subsequently found to have carci-
noma of the lung. Among the other 34 nega-
tive controls one patient with chronic
obstructive airways disease and silicosis was
found to be PCR positive on three of his
specimens. His pulmonary symptoms did not
improve with the standard antibacterial treat-
ment and the culture of his three specimens
later turned out to be positive forM tuberculo-
sis.
As for the effect of antituberculosis treat-
ment on the conversion of findings on smear,
Table 1 Comparison ofPCR assay with smear and culture for detection of
Mycobacterium tuberculosis in clinical specimens
Positive for Positive for
Culture M tuberculosis Atypical Mycobacteria Negative
Smear Positive Negative Positive Negative Positive Negative Subtotal
PCR assay
Positive 53 58 0 0 8- 49* 168
Negative 0 5 3 17 0 326 351
Subtotal 53 63 3 17 8 375 519
*Specimens were taken from patients receiving antituberculosis treatment.
culture, and PCR, 70% of the cases were still
positive by PCR after 4 weeks of treatment
(table 2) while only 32% of these patients
remained culture positive. Although antitu-
berculosis treatment was continued on the
basis of the radiographic findings for the six
patients who were already receiving treatment
on admission, three of them remained PCR
positive after another 4 weeks of treatment.
The turnround time required for reporting
of confirmed positive cultures ranged from 26
days to 54 days (mean 34 days) and that for a
confirmed PCR assay including hybridisation
was 3 to 8 days even when the PCR was per-
formed twice a week. Of the total of 168 PCR
positive assays, 14 (8&3%) specimens were
negative for the target band by direct staining
of the agarose gel but only positive after DNA
probing.
Discussion
To define the role of PCR assay in the man-
agement of patients with suspected pul-
monary tuberculosis, we incorporated the
PCR assay into our routine laboratory proce-
dures using sputum specimens sent from
patients who were admitted and followed up
in a chest hospital for various pulmonary con-
ditions. A set of primers from within the
genomic sequences encoding the 38 kilodal-
ton protein was designed for the PCR assay
and found to be specific for the M tuberculosis
complex both on standard strains and clinical
isolates.
When the results of culture and PCR assay
of individual specimens were correlated, false
negative PCR results (8%) were observed
among the smear negative, culture positive
Table 2 Effect offour weeks of standard antituberculosis
treatment on smear, culture, PCR status ofpatients
4 weeks after
On admission treatment
No (%) No (%O)
Patients with radiographic changes
suspicious of tuberculosis
(1) Culture documented tuberculosis n = 41
smear positive 28 (68)* 16 (39)
culture positive 41 (100) 13 (32)t
PCR positive 41 (100)' 29 (70)t
(2) Treated cases on admission n = 6+
smear positive 2 0
culture positive 0 0
PCR positive 5 3
(3) Cases with atypical mycobacteria n = 4
smear positive 2 0
culture positive 4 3
PCR positive 0 0
Patients with acute exacerbation
ofchronic obstructive airways disease
(controls)n = 34
smear positive 0
culture positive 2§
PCR positive
*Significant difference (p < 0 05) by Fisher's exact test (2
tailed)
tSignificant difference (p < 0 005) by Fisher's exact test (2
tailed)
tOne PCR negative patient was subsequently found to have
carcinoma of the lung
§One patient had M tuberculosis (PCR positive) and the other
had M avium intracellulare infection (PCR negative)
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cases and might be related to imperfect
extraction procedures, non-homogeneous dis-
tribution of the mycobacteria in the sputum
samples or the presence of inhibitors.3"' No
culture positive cases were missed if multiple
specimens were sent for each patient in our
series. PCR assay is more sensitive than the
smear for diagnosis of tuberculous infection
before treatment. It is also more sensitive
than the culture after antimicrobial treatment
has been started.
As for some patients who had started treat-
ment before referral for various reasons, PCR
assay was positive in five of our six patients
with radiological lesions suggestive of tuber-
culosis despite up to 2 weeks of treatment.
The only PCR negative case was subsequent-
ly found to have carcinoma of the lung. Three
patients remained PCR positive after another
4 weeks of treatment during which all had
turned smear negative. Thus PCR assay
could be an important adjunct in the diagno-
sis of these treated cases.
No false positive results were found among
patients with culture positive for atypical
mycobacteria and the controls. Thus the
PCR assay reliably distinguished cases with
positive smear or culture due to atypical
mycobacteria from the cases with tuberculo-
sis. As for the 57 PCR positive specimens
which were culture negative, all were taken
from patients already receiving antituberculo-
sis treatment. They should not be considered
as false positive because the drug treatment
could suppress the growth of mycobacteria
despite continued shedding of these organ-
isms into the sputum. Culture has conven-
tionally been regarded as the gold standard
for the evaluation of new diagnostic tech-
niques, the data from our prospective study
showed that the ability of PCR assay to detect
non-viable or non-culturable mycobacterium
after treatment is an additional advantage
over this conventional method. The clinical
importance of persistently positive PCR
assays despite antituberculosis treatment in
some cases still awaits further follow up
study.
An extensive prospective study was report-
ed by Brisson Noel et al, who compared the
clinical features, mycobacterial culture, and
the PCR assay results of 514 specimens from
318 patients with or without suspected tuber-
culosis. The nature of patients' specimens
used in this study was diverse and these
included gastric aspirate (21%), sputum
(18%), buffy coat (14-5%), and others
(46-5%). Though multiple specimens were
obtained from some patients, no longitudinal
follow up study was done and results of
mycobacterial culture were not available for
analysis in 13-2% of these specimens. In con-
trast to the findings of the present study, a
longitudinal follow up study of 425 speci-
mens from 51 patients with pulmonary dis-
eases was carried out with clearly defined
clinical criteria of enrolment and a complete
set of conventional culture data correlating
with PCR. A control group of 34 patients
yielding 94 sputum samples was chosen to
guard the assay. The results of the conven-
tional culture, smear, and PCR assay before
and 4 weeks after antituberculosis treatment
were analysed.
With respect to the methodology, the two
PCR assays used by Brisson-Noel et al were
based on the amplification of the 65 kilodal-
ton gene or the insertion sequence 6110. An
overall sensitivity of 97 4% was achieved
which was similar to that of the present study.
There were six false negative, three false posi-
tive, and four misidentified strains. Southern
hybridisation using 12P-labelled or horseradish
peroxidase labelled probes were used to con-
firm the identity of the amplicon. The corre-
lation of findings on the gel and the Southern
hybridisation was not given. Detection of
PCR inhibitors was achieved by using PUC
91 plasmid target DNA and TEMA/TEMB
primers in control experiments. Inhibitors
were found in 16% of the buffy coat samples,
6-5% of the gastric aspirates and 3-2% of the
sputum samples. Pretreatment with guanidi-
um thiocyanate was proposed to reduce false
negative results. In the present study the PCR
assay was based on the amplification of the
38 kilodalton gene which is specific for
M tuberculosis complex. No false positive
results were found in specimens positive for
atypical mycobacteria. The target band pre-
sent on the agarose gel correlated with the
Southern hybridisation in 91-7% of the posi-
tive assays. The remaining gel negative probe
positive assays (8 3%) could be related to the
low amount of target DNA present in the
sample or presence of inhibitors. The use of
32P-labelled probes was a setback to the
routine application of this technique in clini-
cal laboratories. We have already tested the
use of digoxigenin-1 1-ddUTP (Boehringer
Mannheim) labelled probes and detection by
alkaline phosphatase catalysed chemilumines-
cent substrate AMPPD (3-(2'-spiroadaman-
tane)-4-methoxy-4-(3"-phosphoryloxy)-phen-
yl-1,2-dioxetane) in 52 specimens which sug-
gested similar sensitivity to 32P-labelled probe
(unpublished data). However, the recurrent
cost of using these non-radioactive agents was
higher. Another alternative to this problem is
to use nested PCR, as the primer sequences
used in this study were in between the primer
sequences (MT-1 and MT-2) used by
Sjobring et al. Though internal controls to
detect inhibitors were not used in the present
study, control PCR with primers for specific
amplification of the DR-[ gene in the HLA-
class II region would be incorporated in fur-
ther follow up studies.'2
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